aim
studi
investig
effect
porcin
reproduct
respiratori
syndrom
viru
prrsv
infect
develop
immun
respons
pseudorabi
viru
prv
vaccin
pig
pig
intranas
inocul
european
prrsv
strain
lelystad
viru
ter
huurn
vaccin
intramuscularli
prv
week
later
lvprv
group
control
pig
vaccin
prv
prv
group
eight
week
prv
vaccin
pig
group
challeng
intranas
wildtyp
prv
measur
lymphoprolif
cytolyt
respons
prv
peripher
blood
mononuclear
cell
pbmc
isol
blood
sampl
addit
serum
sampl
examin
antibodi
prv
lv
one
week
prv
vaccin
pbmc
prolifer
abundantli
prv
group
howev
lvprv
group
lymphoprolif
respons
declin
week
wherea
prv
group
lymphoprolif
respons
high
week
declin
thereaft
p
challeng
lymphoprolif
respons
week
earlier
consist
higher
prv
group
lvprv
group
kill
higher
week
prv
vaccin
week
prv
challeng
respect
prv
group
compar
respect
lvprv
group
p
howev
later
vaccin
challeng
cytolyt
respons
ident
group
antibodi
titr
prv
develop
equal
group
challeng
prv
viru
isol
group
result
conclud
although
prrsv
infect
caus
chang
time
cours
tlymphocyt
respons
prv
vaccin
prrsv
infect
inhibit
develop
vaccineinduc
protect
prv
porcin
reproduct
respiratori
syndrom
viru
prrsv
posit
strand
rna
viru
caus
reproduct
failur
late
term
gestat
sow
respiratori
diseas
pig
age
viru
primarili
infect
destroy
alveolar
macrophag
import
host
defenc
lung
therefor
prrsvinfect
pig
may
suscept
secondari
infect
sinc
prrsv
occur
endem
mani
countri
may
host
defenc
mechan
possibl
prrsv
infect
interfer
vaccin
prv
previou
studi
effect
prrsv
infect
secondari
infect
experiment
condit
contradictori
galina
et
al
describ
clinic
sign
mening
bacteraemia
streptococcu
sui
infect
pig
preinocul
prrsv
thacker
et
al
describ
sever
persist
pneumon
lesion
clinic
respiratori
diseas
mycoplasma
hyopneumonia
infect
follow
prrsv
infect
van
reeth
et
al
reeth
et
al
describ
sever
diseas
dual
infect
prrsv
porcin
respiratori
coronaviru
viru
compar
singl
infect
contrast
other
describ
prrsv
infect
clinic
sign
diseas
infect
pasteurella
multocida
haemophilu
parasui
sui
salmonella
cholerasui
cooper
et
al
addit
albina
et
al
could
demonstr
immunosuppress
effect
prrsv
pseudorabi
viru
prv
glycoprotein
immunis
describ
enhanc
antibodi
respons
challeng
prv
ill
sever
diseas
outcom
infect
microorgan
due
earlier
prrsv
infect
describ
studi
focuss
increas
ill
patholog
alter
secondari
infect
prrsvinfect
pig
howev
effect
prrsv
cellular
immun
respons
secondari
infect
clear
therefor
examin
effect
prrsv
infect
develop
cellular
immun
respons
prv
infect
prv
vaccinationchalleng
model
prv
alphaherpesviru
caus
aujeszki
diseas
pig
humor
cellular
immun
appear
involv
develop
protect
immun
respons
prv
previou
report
describ
time
cours
lymphoprolif
cytolyt
respons
prv
infect
challeng
detail
kimman
et
al
de
bruin
et
al
therefor
use
prv
model
investig
immunosuppress
effect
prrsv
prv
vaccin
challeng
pig
investig
develop
humor
lymphoprolif
cytolyt
respons
prv
pig
inocul
prrsv
prior
prv
vaccin
prrsv
stock
inocul
prepar
alveolar
macrophag
describ
wensvoort
et
al
pig
inocul
prrsv
strain
lelystad
viru
ter
huurn
lvth
prv
stock
vaccin
challeng
prepar
cell
kasza
et
al
secondari
porcin
kidney
cell
respect
describ
kimman
et
al
pig
vaccin
avirul
mutant
strain
ge
prv
de
wind
et
al
kimman
et
al
pig
challeng
wildtyp
prv
strain
mcferran
dow
strain
also
use
infect
target
cell
cytolyt
assay
describ
kimman
et
al
minnesota
miniatur
pig
institut
inbr
antigen
complex
sla
haplotyp
dd
sach
et
al
kept
pathogenfre
condit
pig
born
unvaccin
sow
antibodi
prv
prrsv
pig
randomli
alloc
two
group
hous
separ
six
pig
intranas
inocul
ml
prrsv
strain
lvth
concentr
tcid
ml
per
nostril
five
control
spf
pig
left
uninocul
week
group
vaccin
intramuscularli
plaqueform
unit
pfu
ml
prv
strain
pig
subsequ
challeng
intranas
pfuml
viru
week
prv
vaccin
blood
sampl
taken
weekli
start
week
week
lv
inocul
rectal
temperatur
record
daili
day
lv
inocul
day
prv
challeng
bodi
weight
record
weekli
interv
month
pig
consid
fever
bodi
temperatur
equal
growth
perform
assess
calcul
mean
rel
daili
gain
mrdg
bodi
weight
accord
stellman
et
al
ethic
committe
anim
experi
idlelystad
approv
experi
tabl
pbmc
isol
cultur
done
previous
describ
kimman
et
al
pbmc
stimul
vitro
day
neg
celllys
cell
infecti
prv
viru
cytolyt
assay
pbmc
use
directli
direct
kill
stimul
day
vitro
indirect
kill
describ
de
bruin
et
al
prolifer
pbmc
measur
hthymidin
incorpor
describ
de
bruin
et
al
express
delta
count
ie
number
count
virusstimul
pbmc
minu
number
count
neg
celllysatestimul
pbmc
prolifer
investig
start
week
lv
inocul
weekli
interv
week
lv
inocul
measur
subsequ
prv
inocul
follow
target
cell
use
cytolyt
assay
prvinfect
uninfect
cell
retroviru
immortalis
blymphoblastoid
cell
line
haplotyp
dd
sla
kaeffer
et
al
cell
cell
line
human
erythroleukemia
cell
atcc
rockvil
md
cell
use
assess
kill
porcin
nk
cell
pescovitz
et
al
infect
cell
obtain
infect
cell
h
start
cytolyt
assay
viru
multipl
infect
cell
label
incub
variou
number
cell
volum
ml
serumfre
medium
contain
mci
cr
amersham
den
bosch
netherland
h
rock
n
roller
labinco
breda
netherland
label
cell
wash
three
time
rpmi
complet
medium
volum
ml
medium
contain
cell
ad
well
vbottom
microtitr
plate
nunc
life
technolog
breda
netherland
cytolyt
activ
effector
cell
measur
cr
releas
volum
ml
medium
contain
effector
cell
ml
medium
contain
crlabel
target
cell
mix
order
obtain
effector
target
ratio
plate
centrifug
min
maxim
releas
cr
determin
ad
ml
triton
spontan
releas
determin
well
contain
effector
cell
kill
target
cell
determin
measur
releas
cr
supernat
incub
period
h
volum
ml
supernat
mix
ml
optiphas
supermix
liquid
eg
g
instrument
nieuwegein
netherland
radioact
measur
wallac
microbetaplu
eg
g
instrument
nieuwegein
netherland
percentag
cr
releas
calcul
cpm
experiment
releas
cpm
spontan
releas
cpm
maxim
releas
cpm
spontan
releas
direct
kill
investig
day
prv
vaccin
indirect
kill
investig
week
lv
inocul
week
lv
inocul
measur
weekli
interv
subsequ
prv
inocul
blood
sampl
collect
pig
day
lv
inocul
weekli
interv
prv
inocul
serum
sampl
store
sera
test
presenc
viru
neutralis
antibodi
direct
prv
viru
neutralis
test
vn
titr
describ
kimman
et
al
sera
test
presenc
viru
antibodi
direct
prrsv
immunoperoxidas
monolay
assay
ipma
presenc
prrsv
viru
isol
describ
wensvoort
et
al
prv
viru
excret
monitor
collect
swab
specimen
oropharyng
uid
opf
day
challeng
day
challeng
swab
specimen
extract
ml
dulbecco
minim
essenti
medium
supplement
foetal
bovin
serum
antibiot
determin
viru
content
per
gram
opf
measur
weight
centrifug
swab
kimman
et
al
amount
prv
excret
quantit
titrat
viru
monolay
describ
kimman
et
al
differ
lymphoprolif
respons
kill
activ
vn
antibodi
titr
mrdg
test
statist
analysi
varianc
anova
test
homogen
varianc
within
group
barlett
test
level
set
lv
antibodi
detect
week
lv
inocul
ipma
respons
peak
week
lv
inocul
titr
log
declin
thereaft
week
postlv
inocul
antibodi
lv
titr
log
still
detect
prv
vn
antibodi
detect
week
prv
vaccin
ge
prvstrain
lvprv
prv
group
viru
neutralis
assay
titr
log
challeng
prv
increas
antibodytitr
observ
differ
observ
develop
humor
respons
group
contrast
antibodytitr
lv
antibodytitr
prv
vaccin
challeng
decreas
experi
week
one
week
prv
vaccin
pbmc
prvinfect
pig
prolifer
abundantli
vitro
group
stimul
prv
fig
prolifer
pbmc
tend
higher
statist
prv
group
cpm
lvprv
group
cpm
p
respons
peak
week
prv
vaccin
group
lvprv
group
lymphoprolif
respons
declin
week
later
wherea
prv
group
lymphoprolif
respons
remain
high
week
declin
thereaft
prolifer
higher
p
prv
group
lvprv
group
week
prv
vaccin
contrast
vn
antibodi
lymphoprolif
respons
increas
challeng
wildtyp
viru
fig
group
secondari
lymphoprolif
respons
start
week
challeng
prv
group
week
challeng
lvprv
group
p
prv
challeng
prolifer
pbmc
prv
stimul
consist
lower
lvprv
group
prv
group
p
fig
time
cours
cytolyt
activ
indirect
kill
lv
prv
inocul
pbmc
prv
lvprv
group
stimul
vitro
viru
kill
ie
kill
prvinfect
cell
kill
uninfect
cell
increas
week
prv
vaccin
prvinfect
target
cell
kill
compar
uninfect
target
cell
group
kill
cell
detect
period
least
week
challeng
prvinfect
target
cell
kill
compar
uninfect
target
cell
cell
poorli
kill
prv
vaccin
kill
higher
week
prv
vaccin
week
prv
challeng
respect
prv
group
compar
respect
lvprv
group
p
fig
howev
later
prv
vaccin
kill
compar
group
cell
poorli
kill
group
prv
lvprv
group
week
challeng
day
prv
vaccin
directli
use
pbmc
prv
group
kill
prvinfect
cell
pbmc
lvprv
group
p
contrast
day
prv
vaccin
pbmc
prv
lvprv
group
kill
prvinfect
cell
equal
well
kill
cell
detect
pig
lvprv
group
fever
inocul
lv
day
lv
inocul
prv
vaccin
day
lv
infect
contrast
pig
prv
group
fever
vaccin
fig
pig
group
fever
challeng
lv
isol
sera
pig
lv
isol
day
pig
day
pig
day
pig
lv
inocul
prv
isol
opf
group
challeng
prv
mean
daili
weight
gain
differ
lv
prv
inocul
group
pig
clinic
sign
prrsv
diseas
lv
inocul
except
fever
clinic
sign
aujeszki
diseas
prv
inocul
result
show
prrsv
infect
prior
prv
vaccin
caus
differ
level
time
cours
cellular
immun
respons
prv
lymphoprolif
respons
tend
quicker
longer
week
p
prv
group
lvprv
group
prv
vaccin
lymphoprolif
respons
also
quicker
week
consist
higher
prv
group
lvprv
group
prv
challeng
p
furthermor
use
vitro
prvstimul
pbmc
cytolyt
respons
prv
reach
maximum
week
prv
vaccin
week
prv
challeng
prvgroup
wherea
lvprv
group
p
later
vaccin
challeng
cytolyt
respons
compar
group
kinet
cytolyt
respons
prv
vaccin
describ
studi
de
bruin
et
al
indic
lvprv
group
studi
reach
maximum
level
cytolyt
respons
wherea
prv
group
pbmc
use
directli
also
observ
higher
cytolyt
respons
prv
day
prv
vaccin
prv
group
lvprv
group
p
result
indic
mild
immunosuppress
effect
prrsv
infect
develop
cellular
immun
respons
prv
vaccin
challeng
explan
lower
tlymphocyt
respons
may
prrsv
infect
monocyt
macrophag
may
hamper
antigenpresent
therebi
suppress
abil
pbmc
prolifer
although
prrsv
clearli
affect
time
cours
cellular
immun
respons
prv
infect
effect
humor
respons
prv
detect
vaccin
challeng
lvprv
group
contrast
brun
et
al
observ
enhanc
secondari
humor
respons
challeng
albina
et
al
molitor
et
al
also
observ
enhanc
humor
respons
challeng
prv
earlier
prrsv
infect
possibl
prrsv
infect
stimul
humor
respons
howev
explan
discrep
use
potent
vaccin
strain
induc
protect
increas
antibodytitr
kimman
et
al
kimman
et
al
de
bruin
et
al
could
detect
differ
protect
prv
challeng
group
neg
effect
prrsv
infect
protect
prv
vaccin
exclud
less
potent
vaccin
strain
use
howev
vaccin
strain
use
strain
induc
high
cellular
immun
respons
de
bruin
et
al
eventu
neg
effect
prrsv
infect
develop
cellular
immun
respons
could
measur
well
weight
loss
differ
mean
daili
weight
gain
observ
group
furthermor
prv
excret
challeng
indic
optim
protect
observ
clinic
sign
fever
day
lv
inocul
day
prv
vaccin
lvprv
group
van
reeth
et
al
also
describ
fever
clinic
sign
dual
infect
prrsv
porcin
respiratori
coronaviru
swine
viru
although
measur
fever
lv
inocul
prv
vaccin
could
detect
clinic
sign
aujeszki
diseas
vaccin
prv
mutant
strain
caus
mild
clinic
sign
kimman
et
al
de
bruin
et
al
obvious
even
though
pig
recov
earlier
prrsv
infect
prv
mutant
strain
could
caus
aujeszki
diseas
thu
although
tlymphocyt
respons
diminish
prv
pig
fever
lvprv
group
pig
clinic
protect
prv
challeng
conclus
demonstr
prrsv
infect
prior
prv
vaccin
mildli
affect
level
time
cours
tlymphocyt
respons
prv
despit
differ
prrsv
infect
capac
ge
prv
strain
induc
protect
wildtyp
prv
challeng
